X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-12-05 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.96 | +10,000 | 766,460 | +1% | +$9,600 | ||||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $31.19 | -5,358 | 19,798 | -21% | -$167,115 | |||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $31.13 | -15,001 | 62,554 | -19% | -$466,959 | |||||
| DM | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $31.25 | -9,803 | 15,809 | -38% | -$306,322 | |||||
| D | 2025-12-04 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | CFO, CBO | S - Sale+OE | $45.18 | -20,000 | 0 | -100% | -$903,600 | |||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Capps Kathleen S. | See Remarks | S - Sale | $14.23 | -323 | 8,377 | -4% | -$4,596 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Trout Harry R. III | See Remarks | S - Sale | $14.23 | -542 | 16,348 | -3% | -$7,713 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Rottinghaus Scott T. | Chief Medical Officer | S - Sale | $14.23 | -798 | 21,792 | -4% | -$11,356 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Luu Brendan | Chief Business Officer | S - Sale | $14.23 | -1,394 | 38,329 | -4% | -$19,837 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Kieffer Tara Lynn | Chief Product Strategy Officer | S - Sale | $14.23 | -2,106 | 30,620 | -6% | -$29,968 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Or Yat Sun | Chief Scientific Officer | S - Sale | $14.23 | -2,390 | 371,392 | -1% | -$34,010 | ||||||
2025-12-05 | ENTA | Enanta Pharmaceuticals Inc | Luly Jay R. | Pres, CEO | S - Sale | $14.23 | -4,743 | 858,026 | -1% | -$67,493 | ||||||
| D | 2025-12-04 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $10.19 | -68,897 | 0 | -100% | -$701,909 | |||||
2025-12-03 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $18.75 | -31,067 | 277,695 | -10% | -$582,501 | ||||||
| DM | 2025-12-02 | TENX | Tenax Therapeutics, Inc. | Rich Stuart | Chief Medical Officer | P - Purchase | $9.12 | +5,000 | 7,654 | +188% | +$45,622 | |||||
| D | 2025-12-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $65.95 | -52,486 | 50,660 | -51% | -$3,461,452 | |||||
| D | 2025-12-03 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $78.62 | -733 | 6,666 | -10% | -$57,628 | |||||
2025-12-03 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, CLO | S - Sale | $39.77 | -110,000 | 889,915 | -11% | -$4,375,008 | ||||||
| DM | 2025-12-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $477.64 | -8,000 | 644,489 | -1% | -$3,821,130 | |||||
| D | 2025-12-03 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $30.00 | -3,748 | 65,740 | -5% | -$112,447 | |||||
2025-12-03 | VRTX | Vertex Pharmaceuticals Inc / Ma | Wagner Charles F Jr | EVP, CO, FO | S - Sale | $456.00 | -14,000 | 37,725 | -27% | -$6,384,000 | ||||||
2025-12-04 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $24.71 | -82,997 | 1,321,283 | -6% | -$2,050,599 | ||||||
2025-12-03 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $449.99 | -4,500 | 46,793 | -9% | -$2,024,955 | ||||||
2025-12-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $20.72 | -2,662 | 268,877 | -1% | -$55,157 | ||||||
| D | 2025-12-04 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $205.62 | -10,699 | 588,335 | -2% | -$2,199,915 | |||||
| D | 2025-12-03 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | Exec COB | S - Sale+OE | $449.20 | -63,781 | 24,467 | -72% | -$28,650,337 | |||||
2025-12-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $20.72 | -880 | 87,510 | -1% | -$18,234 | ||||||
2025-12-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $20.72 | -144 | 94,729 | 0% | -$2,984 | ||||||
2025-12-03 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $449.00 | -347 | 15,306 | -2% | -$155,803 | ||||||
| D | 2025-12-02 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale+OE | $10.00 | -46,657 | 48,473 | -49% | -$466,570 | |||||
| M | 2025-12-02 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $7.79 | +262,027 | 5,570,607 | +5% | +$2,039,901 | |||||
| DM | 2025-12-02 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.61 | -6,500 | 0 | -100% | -$23,481 | |||||
| DM | 2025-12-02 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $145.66 | -79,973 | 7,351,729 | -1% | -$11,648,582 | |||||
| D | 2025-12-02 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $5.57 | -107,920 | 2,504,792 | -4% | -$601,114 | |||||
| D | 2025-12-02 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale+OE | $5.57 | -147,780 | 841,719 | -15% | -$823,135 | |||||
2025-12-02 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $3.46 | -22,506 | 99,000 | -19% | -$77,871 | ||||||
2025-12-02 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $3.46 | -9,072 | 39,938 | -19% | -$31,395 | ||||||
| DM | 2025-12-03 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $41.00 | -7,040 | 66,600 | -10% | -$288,607 | |||||
| M | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.92 | -128,185 | 3,068,278 | -4% | -$117,623 | |||||
| M | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | Former 10% Owner | S - Sale | $0.92 | -199,732 | 4,784,111 | -4% | -$183,275 | |||||
| M | 2025-12-02 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | Former 10% Owner | S - Sale | $0.92 | -199,732 | 4,784,111 | -4% | -$183,275 | |||||
| D | 2025-12-04 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale+OE | $575.34 | -2,400 | 150,074 | -2% | -$1,380,816 | |||||
| M | 2025-12-02 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $5.68 | -150,000 | 5,682,207 | -3% | -$851,700 | |||||
| M | 2025-12-02 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.11 | -6,000 | 420,818 | -1% | -$60,640 | |||||
2025-12-02 | BMEA | Biomea Fusion, Inc. | Hitchcock Michael J.M. | Interim CEO | P - Purchase | $0.99 | +100,000 | 115,000 | +667% | +$99,180 | ||||||
| D | 2025-12-03 | VERA | Vera Therapeutics, Inc. | Turner William D. | Chief Regulatory Officer | S - Sale+OE | $40.00 | -10,000 | 22,500 | -31% | -$400,000 | |||||
| D | 2025-11-24 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $13.45 | -3,813 | 39,728 | -9% | -$51,289 | |||||
| A | 2025-11-25 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $0.97 | +10,500 | 1,041,521 | +1% | +$10,144 | |||||
| AM | 2025-11-26 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.11 | +72,000 | 1,113,521 | +7% | +$79,849 | |||||
2025-12-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $29.02 | -15,000 | 686,907 | -2% | -$435,356 | ||||||
| D | 2025-12-02 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $80.08 | -20,000 | 1,235 | -94% | -$1,601,526 | |||||
| D | 2025-12-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $79.52 | -20,000 | 117,896 | -15% | -$1,590,490 | |||||
| D | 2025-12-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $79.53 | -5,000 | 10,523 | -32% | -$397,632 | |||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $30.22 | -4,020 | 15,156 | -21% | -$121,468 | |||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $30.22 | -2,136 | 51,305 | -4% | -$64,541 | |||||
2025-11-28 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale | $45.01 | -97 | 45,505 | 0% | -$4,366 | ||||||
| DM | 2025-12-02 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $30.22 | -4,576 | 19,612 | -19% | -$138,268 | |||||
2025-12-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $79.77 | -40,000 | 2,701,370 | -1% | -$3,190,796 | ||||||
| D | 2025-12-01 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $10.01 | -14,587 | 1,137,282 | -1% | -$146,011 | |||||
| A | 2025-11-25 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale | $80.90 | -4,500 | 787 | -85% | -$364,070 | |||||
| D | 2025-12-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $32.98 | -3,333 | 84,974 | -4% | -$109,929 | |||||
2025-12-01 | IONS | Ionis Pharmaceuticals Inc | Wender Joseph H | Dir | S - Sale | $80.82 | -28,000 | 52,035 | -35% | -$2,262,848 | ||||||
| D | 2025-12-02 | MDGL | Madrigal Pharmaceuticals, Inc. | Dier Mardi | EVP, CFO | S - Sale+OE | $578.34 | -4,173 | 10,440 | -29% | -$2,413,416 | |||||
| M | 2025-12-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $37.53 | +6,864 | 380,964 | +2% | +$257,610 | |||||
2025-12-01 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $30.23 | -1,657 | 150,641 | -1% | -$50,091 | ||||||
2025-12-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $30.21 | -10,000 | 79,744 | -11% | -$302,133 | ||||||
2025-12-02 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $79.07 | -3,428 | 349,964 | -1% | -$271,052 | ||||||
2025-12-01 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.87 | -69,582 | 690,142 | -9% | -$2,773,956 | ||||||
2025-12-01 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.92 | -41,575 | 227,994 | -15% | -$1,659,489 | ||||||
2025-12-02 | ENTA | Enanta Pharmaceuticals Inc | Capps Kathleen S. | See Remarks | S - Sale | $13.96 | -207 | 8,700 | -2% | -$2,890 | ||||||
2025-12-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $195.84 | -467 | 44,121 | -1% | -$91,457 | ||||||
2025-12-02 | ENTA | Enanta Pharmaceuticals Inc | Trout Harry R. III | See Remarks | S - Sale | $13.96 | -380 | 16,890 | -2% | -$5,305 | ||||||
| D | 2025-12-01 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $7.82 | -150,000 | 18,000 | -89% | -$1,173,255 | |||||
2025-12-01 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $14.35 | -6,580 | 175,756 | -4% | -$94,418 | ||||||
2025-12-01 | ANNX | Annexon, Inc. | Choi Jung | Dir | P - Purchase | $4.19 | +33,000 | 33,000 | New | +$138,270 | ||||||
2025-12-01 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $4.47 | +4,115 | 50,290 | +9% | +$18,394 | ||||||
| D | 2025-12-01 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $35.01 | -20,000 | 92,083 | -18% | -$700,202 | |||||
| D | 2025-12-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $45.02 | -5,000 | 66,837 | -7% | -$225,100 | |||||
| D | 2025-12-01 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $206.98 | -8,895 | 83,111 | -10% | -$1,841,101 | |||||
2025-12-01 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $5.00 | -10,000 | 492,784 | -2% | -$50,008 | ||||||
2025-12-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $7.01 | -16,667 | 1,320,176 | -1% | -$116,781 | ||||||
| D | 2025-12-02 | CYTK | Cytokinetics Inc | Henderson John T | Dir | S - Sale+OE | $63.90 | -8,750 | 74,661 | -10% | -$559,125 | |||||
| D | 2025-12-02 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $63.89 | -2,200 | 140,610 | -2% | -$140,558 | |||||
| M | 2025-11-28 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $60.00 | -1,000 | 42,048 | -2% | -$60,000 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $32.19 | -1,072 | 591,788 | 0% | -$34,508 | |||||
2025-12-01 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $32.19 | -221 | 141,218 | 0% | -$7,114 | ||||||
| D | 2025-12-01 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $479.99 | -21,000 | 8,142 | -72% | -$10,079,696 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $32.19 | -1,166 | 353,823 | 0% | -$37,534 | |||||
| DM | 2025-12-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $481.61 | -8,000 | 644,489 | -1% | -$3,852,846 | |||||
2025-12-01 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $32.19 | -303 | 155,031 | 0% | -$9,754 | ||||||
| D | 2025-12-01 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $479.92 | -22,500 | 2,648 | -89% | -$10,798,079 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $32.19 | -693 | 175,868 | 0% | -$22,308 | |||||
| D | 2025-11-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $108.58 | -4,000 | 48,034 | -8% | -$434,319 | |||||
| D | 2025-12-01 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $32.19 | -831 | 154,506 | -1% | -$26,750 | |||||
| M | 2025-11-28 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $42.10 | -7,040 | 43,640 | -14% | -$296,376 | |||||
| M | 2025-11-28 | BMEA | Biomea Fusion, Inc. | Erdtmann Rainer M | See Remarks | P - Purchase | $1.09 | +50,000 | 2,542,820 | +2% | +$54,552 | |||||
| D | 2025-12-01 | MIRM | Mirum Pharmaceuticals, Inc. | Grey Michael G | Dir | S - Sale+OE | $74.00 | -50,000 | 280,160 | -15% | -$3,700,000 | |||||
| D | 2025-12-01 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale+OE | $66.72 | -28,064 | 9,977 | -74% | -$1,872,430 | |||||
2025-12-01 | CYTK | Cytokinetics Inc | Harrington Robert Arthur | Dir | S - Sale | $66.80 | -2,150 | 18,542 | -10% | -$143,620 | ||||||
| D | 2025-11-26 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $20.00 | -29,501 | 44,703 | -40% | -$590,020 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |